Project Grant R21NS142733
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to develop a novel cellular model for investigating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will directly convert patient-derived fibroblasts into neurons, preserving the epigenetic age of the starting cells, in order to...
- This Project Grant award of $374,349 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports the development and optimization of a new animal model for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The goal is to create a mouse model that accurately recapitulates the human disease spectrum by incorporating an acetylation-mimicking...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,001,864 to Harvard University to investigate the subcellular mechanisms underlying the selective vulnerability of specific neuron subtypes in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will quantitatively study the localization of RNA, proteins, and translational regulation in the synapses and soma of vulnerable corticospinal neurons (CSN) and...
- This $3,081,936 federal Project Grant award was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The award supports research at the University of California, San Diego (UCSD) to investigate the mechanisms underlying TDP-43 proteinopathies, which are associated with amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease,...
- This federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, consolidates multiple research projects into a single larger R35 grant to enable comprehensive exploration of biological mechanisms underlying neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Parkinson's disease. The...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $2,507,054 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to Synapticure Inc., a for-profit company in Illinois. The award, effective May 9, 2025 through April 30, 2027, supports the development of a novel 3D in vitro platform for modeling genetic and sporadic forms of frontotemporal dementia (FTD). Synapticure's Cortical Brain Spheroids (CBS) system...
- This federal Project Grant award, valued at $737,720.00 and provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research at Case Western Reserve University to investigate the role of the ATAD3A protein in regulating the cytoplasmic accumulation of the TDP43 protein, which is a hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $1,138,538 to Mayo Clinic Jacksonville to expand research into the mechanisms underlying frontotemporal lobar degeneration (FTLD), which causes frontotemporal dementia (FTD) and is genetically linked to amyotrophic lateral sclerosis (ALS). The research aims to investigate key...
- This Project Grant award of $460,625 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is supporting research to investigate the roles of the deubiquitylation pathway in TDP-43 pathology associated with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The research is being conducted by the University of Massachusetts Medical School (UMMS) and...
- This Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to investigate the dysfunction of neuroimmune-related processes in animal models of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) associated with TAR DNA-binding protein 43 (TDP-43). The $251,250 award, effective from Apr 1, 2025 to Mar 31,...
This $438,606 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is supporting research at Northwestern University to establish novel human models that investigate the mechanistic interaction between neurotrauma and amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD). The research utilizes ALS/FTD patient-specific induced pluripotent stem cell (iPSC) derived neuronal cultures and a custom-built device that applies biofidelic mechanical stretch-induced trauma in vitro. This work aims to better understand the shared neuropathology and clinical heterogeneity observed in patients with ALS/FTD, particularly those with the C9ORF72 genetic mutation, and the potential role of environmental factors like neurotrauma as an additional trigger. The project will run from August 1, 2025 to July 31, 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $438.6k | 7/30/25 |